Affimed (AFMD) Cut to Buy at ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Affimed (NASDAQ:AFMD) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday morning.

AFMD has been the subject of several other research reports. BMO Capital Markets upped their price objective on shares of Affimed from $4.00 to $5.00 and gave the company an outperform rating in a research note on Tuesday, August 28th. Zacks Investment Research upgraded shares of Affimed from a sell rating to a hold rating in a research note on Tuesday, June 19th. Jefferies Financial Group upgraded shares of Affimed from a hold rating to a buy rating and upped their price objective for the company from $1.80 to $4.00 in a research note on Tuesday, August 28th. Finally, BidaskClub upgraded shares of Affimed from a strong sell rating to a sell rating in a research note on Friday, August 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $3.75.

NASDAQ AFMD opened at $4.55 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.33 and a current ratio of 5.36. Affimed has a 1 year low of $1.15 and a 1 year high of $7.35.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its stake in Affimed by 38.8% in the second quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 49,610 shares in the last quarter. Barclays PLC boosted its stake in Affimed by 385.3% in the first quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 51,573 shares in the last quarter. Stanley Laman Group Ltd. acquired a new position in Affimed in the second quarter valued at $100,000. Dimensional Fund Advisors LP boosted its stake in Affimed by 28.8% in the first quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after acquiring an additional 71,545 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Affimed in the second quarter valued at about $165,000. Institutional investors own 41.11% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Article: How to Track your Portfolio in Google Finance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply